ESPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ESPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Esperion Therapeutics's float shares is 188.89 Mil. Esperion Therapeutics's total shares outstanding is 189.40 Mil. Esperion Therapeutics's float percentage of total shares outstanding is 99.73%.
Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Esperion Therapeutics's Insider Ownership is 2.45%.
Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Esperion Therapeutics's Institutional Ownership is 14.69%.
It is the percentage of float shares out of the total shares outstanding.
Esperion Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:
Float Percentage of Total Shares Outstanding | = | Float Shares | / | Total Shares Outstanding |
= | 188.89 | / | 189.40 | |
= | 99.73% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eric Warren | officer: Chief Commercial Officer | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
J Martin Carroll | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Stephen Rocamboli | director | C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
Sheldon L. Koenig | officer: Chief Operating Officer | C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Joanne M. Foody | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Benjamin Looker | officer: General Counsel | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Benjamin Halladay | officer: Chief Financial Officer | ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Alan Fuhrman | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Timothy M Mayleben | director, officer: Pres & Chief Executive Officer | 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108 |
Ashley Hall | officer: Chief Development Officer | C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
Tracy M Woody | director | 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
Richard Bartram | officer: Chief Financial Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Nicole Vitullo | director, 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
From GuruFocus
By sperokesalga sperokesalga • 06-08-2023
By Marketwired • 08-28-2023
By sperokesalga sperokesalga • 05-24-2023
By Marketwired • 09-12-2023
By Marketwired • 07-07-2023
By sperokesalga sperokesalga • 05-12-2023
By GlobeNewswire • 11-11-2023
By GlobeNewswire • 01-19-2024
By sperokesalga sperokesalga • 05-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.